Oppenheimer & Co’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.67M Buy
3,090
+17
+0.6% +$9.57K 0.02% 718
2026
Q1
$1.82M Sell
3,073
-123
-4% -$61.3K 0.02% 624
2025
Q4
$1.56M Sell
3,196
-1,098
-26% -$511K 0.02% 620
2025
Q3
$1.8M Sell
4,294
-502
-10% -$169K 0.02% 647
2025
Q2
$1.38M Buy
4,796
+308
+7% +$92K 0.02% 712
2025
Q1
$1.38M Sell
4,488
-179
-4% -$61.3K 0.02% 667
2024
Q4
$1.65M Sell
4,667
-1,581
-25% -$581K 0.02% 601
2024
Q3
$2.24M Buy
6,248
+1,078
+21% +$364K 0.03% 513
2024
Q2
$1.65M Buy
5,170
+530
+11% +$140K 0.03% 595
2024
Q1
$1.07M Buy
4,640
+699
+18% +$158K 0.02% 719
2023
Q4
$867K Buy
3,941
+505
+15% +$116K 0.02% 756
2023
Q3
$776K Sell
3,436
-3,850
-53% -$887K 0.02% 763
2023
Q2
$1.61M Buy
7,286
+722
+11% +$160K 0.03% 533
2023
Q1
$1.47M Sell
6,564
-659
-9% -$162K 0.03% 551
2022
Q4
$2.01M Sell
7,223
-2,064
-22% -$521K 0.05% 441
2022
Q3
$1.95M Buy
9,287
+2,713
+41% +$607K 0.05% 441
2022
Q2
$1.55M Buy
6,574
+3,256
+98% +$662K 0.03% 535
2022
Q1
$595K Sell
3,318
-396
-11% -$75.4K 0.01% 937
2021
Q4
$803K Buy
3,714
+184
+5% +$36.1K 0.01% 864
2021
Q3
$652K Buy
3,530
+670
+23% +$132K 0.01% 908
2021
Q2
$513K Sell
2,860
-214
-7% -$40.8K 0.01% 1020
2021
Q1
$514K Buy
3,074
+392
+15% +$65.4K 0.01% 954
2020
Q4
$407K Sell
2,682
-34
-1% -$4.46K 0.01% 972
2020
Q3
$274K Sell
2,716
-2,582
-49% -$283K 0.01% 1023
2020
Q2
$641K Buy
+5,298
New +$596K 0.02% 712
2020
Q1
Sell
-5,121
Closed -$451K 1332
2019
Q4
$451K Hold
5,121
0.01% 878
2019
Q3
$408K Buy
5,121
+1,267
+33% +$102K 0.01% 870
2019
Q2
$301K Buy
+3,854
New +$360K 0.01% 1005
2018
Q1
Sell
-1,616
Closed -$239K 1395
2017
Q4
$239K Buy
+1,616
New +$205K 0.01% 1144
2015
Q3
Sell
-2,055
Closed -$357K 1464
2015
Q2
$357K Buy
+2,055
New +$370K 0.01% 1026
2014
Q3
Sell
-4,187
Closed -$371K 1492
2014
Q2
$371K Buy
+4,187
New +$403K 0.01% 970
2013
Q3
Sell
-27,960
Closed -$1.84M 1368
2013
Q2
$1.84M Buy
+27,960
New +$1.8M 0.07% 324

Other funds holding UTHR

Oppenheimer & Co's UTHR Position: Q2 2026 in Review

Oppenheimer & Co increased its United Therapeutics (UTHR) stake by 0.55% in Q2 2026, buying an estimated $9.57K and bringing the position to 3,090 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #718.

Oppenheimer & Co first reported a position in UTHR in Q2 2013 and has held it in 32 quarters since. The position peaked at $2.24M in Q3 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Oppenheimer & Co held 3,090 shares of United Therapeutics worth $1.67M as of Q2 2026.
  • Oppenheimer & Co bought 17 United Therapeutics shares in Q2 2026, an estimated $9.57K.
  • United Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q2 2026, its #718 holding.
  • Oppenheimer & Co first reported a position in United Therapeutics in Q2 2013 and has held it in 32 quarters since.
  • Oppenheimer & Co's United Therapeutics position peaked at $2.24M in Q3 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.